secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0001641172-25-011868
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 3.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir Pharmaceuticals raises $3M via premium equity sale from largest shareholder
--------------------------------------------------------------------------------

- $3 million raised via direct investment by Bayshore Trust (largest shareholder) at $3.00/share, 18% premium to $2.54 close.
- 1 million restricted shares issued; no warrants, no discounts, no convertible features.
- Proceeds to fund Telomir-1 IND submission for a rare disease indication.
- Follows prior $1M investment at $7.00/share and complements $5M undrawn line of credit from same group.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225011868/0001641172-25-011868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225011868/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-011868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer